Inherited Breast Cancer in Nigerian Women

Among Nigerian women, breast cancer is diagnosed at later stages, is more frequently triple-negative disease, and is far more frequently fatal than in Europe or the United States. We evaluated the contribution of an inherited predisposition to breast cancer in this population. Cases were 1,136 women...

Full description

Saved in:
Bibliographic Details
Published inJournal of clinical oncology Vol. 36; no. 28; pp. 2820 - 2825
Main Authors Zheng, Yonglan, Walsh, Tom, Gulsuner, Suleyman, Casadei, Silvia, Lee, Ming K., Ogundiran, Temidayo O., Ademola, Adeyinka, Falusi, Adeyinka G., Adebamowo, Clement A., Oluwasola, Abideen O., Adeoye, Adewumi, Odetunde, Abayomi, Babalola, Chinedum P., Ojengbede, Oladosu A., Odedina, Stella, Anetor, Imaria, Wang, Shengfeng, Huo, Dezheng, Yoshimatsu, Toshio F., Zhang, Jing, Felix, Gabriela E.S., King, Mary-Claire, Olopade, Olufunmilayo I.
Format Journal Article
LanguageEnglish
Published United States American Society of Clinical Oncology 01.10.2018
Subjects
Online AccessGet full text
ISSN0732-183X
1527-7755
1527-7755
DOI10.1200/JCO.2018.78.3977

Cover

Abstract Among Nigerian women, breast cancer is diagnosed at later stages, is more frequently triple-negative disease, and is far more frequently fatal than in Europe or the United States. We evaluated the contribution of an inherited predisposition to breast cancer in this population. Cases were 1,136 women with invasive breast cancer (mean age at diagnosis, 47.5 ± 11.5 years) ascertained in Ibadan, Nigeria. Patients were selected regardless of age at diagnosis, family history, or prior genetic testing. Controls were 997 women without cancer (mean age at interview, 47.0 ± 12.4 years) from the same communities. BROCA panel sequencing was used to identify loss-of-function mutations in known and candidate breast cancer genes. Of 577 patients with information on tumor stage, 86.1% (497) were diagnosed at stage III (241) or IV (256). Of 290 patients with information on tumor hormone receptor status and human epidermal growth factor receptor 2, 45.9% (133) had triple-negative breast cancer. Among all cases, 14.7% (167 of 1,136) carried a loss-of-function mutation in a breast cancer gene: 7.0% in BRCA1, 4.1% in BRCA2, 1.0% in PALB2, 0.4% in TP53, and 2.1% in any of 10 other genes. Odds ratios were 23.4 (95% CI, 7.4 to 73.9) for BRCA1 and 10.3 (95% CI, 3.7 to 28.5) for BRCA2. Risks were also significantly associated with PALB2 (11 cases, zero controls; P = .002) and TP53 (five cases, zero controls; P = .036). Compared with other patients, BRCA1 mutation carriers were younger ( P < .001) and more likely to have triple-negative breast cancer ( P = .028). Among Nigerian women, one in eight cases of invasive breast cancer is a result of inherited mutations in BRCA1, BRCA2, PALB2, or TP53, and breast cancer risks associated with these genes are extremely high. Given limited resources, prevention and early detection services should be especially focused on these highest-risk women.
AbstractList Among Nigerian women, breast cancer is diagnosed at later stages, is more frequently triple-negative disease, and is far more frequently fatal than in Europe or the United States. We evaluated the contribution of an inherited predisposition to breast cancer in this population.PURPOSEAmong Nigerian women, breast cancer is diagnosed at later stages, is more frequently triple-negative disease, and is far more frequently fatal than in Europe or the United States. We evaluated the contribution of an inherited predisposition to breast cancer in this population.Cases were 1,136 women with invasive breast cancer (mean age at diagnosis, 47.5 ± 11.5 years) ascertained in Ibadan, Nigeria. Patients were selected regardless of age at diagnosis, family history, or prior genetic testing. Controls were 997 women without cancer (mean age at interview, 47.0 ± 12.4 years) from the same communities. BROCA panel sequencing was used to identify loss-of-function mutations in known and candidate breast cancer genes.PATIENTS AND METHODSCases were 1,136 women with invasive breast cancer (mean age at diagnosis, 47.5 ± 11.5 years) ascertained in Ibadan, Nigeria. Patients were selected regardless of age at diagnosis, family history, or prior genetic testing. Controls were 997 women without cancer (mean age at interview, 47.0 ± 12.4 years) from the same communities. BROCA panel sequencing was used to identify loss-of-function mutations in known and candidate breast cancer genes.Of 577 patients with information on tumor stage, 86.1% (497) were diagnosed at stage III (241) or IV (256). Of 290 patients with information on tumor hormone receptor status and human epidermal growth factor receptor 2, 45.9% (133) had triple-negative breast cancer. Among all cases, 14.7% (167 of 1,136) carried a loss-of-function mutation in a breast cancer gene: 7.0% in BRCA1, 4.1% in BRCA2, 1.0% in PALB2, 0.4% in TP53, and 2.1% in any of 10 other genes. Odds ratios were 23.4 (95% CI, 7.4 to 73.9) for BRCA1 and 10.3 (95% CI, 3.7 to 28.5) for BRCA2. Risks were also significantly associated with PALB2 (11 cases, zero controls; P = .002) and TP53 (five cases, zero controls; P = .036). Compared with other patients, BRCA1 mutation carriers were younger ( P < .001) and more likely to have triple-negative breast cancer ( P = .028).RESULTSOf 577 patients with information on tumor stage, 86.1% (497) were diagnosed at stage III (241) or IV (256). Of 290 patients with information on tumor hormone receptor status and human epidermal growth factor receptor 2, 45.9% (133) had triple-negative breast cancer. Among all cases, 14.7% (167 of 1,136) carried a loss-of-function mutation in a breast cancer gene: 7.0% in BRCA1, 4.1% in BRCA2, 1.0% in PALB2, 0.4% in TP53, and 2.1% in any of 10 other genes. Odds ratios were 23.4 (95% CI, 7.4 to 73.9) for BRCA1 and 10.3 (95% CI, 3.7 to 28.5) for BRCA2. Risks were also significantly associated with PALB2 (11 cases, zero controls; P = .002) and TP53 (five cases, zero controls; P = .036). Compared with other patients, BRCA1 mutation carriers were younger ( P < .001) and more likely to have triple-negative breast cancer ( P = .028).Among Nigerian women, one in eight cases of invasive breast cancer is a result of inherited mutations in BRCA1, BRCA2, PALB2, or TP53, and breast cancer risks associated with these genes are extremely high. Given limited resources, prevention and early detection services should be especially focused on these highest-risk women.CONCLUSIONAmong Nigerian women, one in eight cases of invasive breast cancer is a result of inherited mutations in BRCA1, BRCA2, PALB2, or TP53, and breast cancer risks associated with these genes are extremely high. Given limited resources, prevention and early detection services should be especially focused on these highest-risk women.
Among Nigerian women, breast cancer is diagnosed at later stages, is more frequently triple-negative disease, and is far more frequently fatal than in Europe or the United States. We evaluated the contribution of an inherited predisposition to breast cancer in this population. Cases were 1,136 women with invasive breast cancer (mean age at diagnosis, 47.5 ± 11.5 years) ascertained in Ibadan, Nigeria. Patients were selected regardless of age at diagnosis, family history, or prior genetic testing. Controls were 997 women without cancer (mean age at interview, 47.0 ± 12.4 years) from the same communities. BROCA panel sequencing was used to identify loss-of-function mutations in known and candidate breast cancer genes. Of 577 patients with information on tumor stage, 86.1% (497) were diagnosed at stage III (241) or IV (256). Of 290 patients with information on tumor hormone receptor status and human epidermal growth factor receptor 2, 45.9% (133) had triple-negative breast cancer. Among all cases, 14.7% (167 of 1,136) carried a loss-of-function mutation in a breast cancer gene: 7.0% in BRCA1, 4.1% in BRCA2, 1.0% in PALB2, 0.4% in TP53, and 2.1% in any of 10 other genes. Odds ratios were 23.4 (95% CI, 7.4 to 73.9) for BRCA1 and 10.3 (95% CI, 3.7 to 28.5) for BRCA2. Risks were also significantly associated with PALB2 (11 cases, zero controls; P = .002) and TP53 (five cases, zero controls; P = .036). Compared with other patients, BRCA1 mutation carriers were younger ( P < .001) and more likely to have triple-negative breast cancer ( P = .028). Among Nigerian women, one in eight cases of invasive breast cancer is a result of inherited mutations in BRCA1, BRCA2, PALB2, or TP53, and breast cancer risks associated with these genes are extremely high. Given limited resources, prevention and early detection services should be especially focused on these highest-risk women.
Author Anetor, Imaria
Felix, Gabriela E.S.
Adeoye, Adewumi
Walsh, Tom
Odetunde, Abayomi
Wang, Shengfeng
Lee, Ming K.
Yoshimatsu, Toshio F.
King, Mary-Claire
Babalola, Chinedum P.
Olopade, Olufunmilayo I.
Gulsuner, Suleyman
Zheng, Yonglan
Falusi, Adeyinka G.
Odedina, Stella
Zhang, Jing
Casadei, Silvia
Ogundiran, Temidayo O.
Adebamowo, Clement A.
Oluwasola, Abideen O.
Ojengbede, Oladosu A.
Ademola, Adeyinka
Huo, Dezheng
Author_xml – sequence: 1
  givenname: Yonglan
  surname: Zheng
  fullname: Zheng, Yonglan
  organization: Yonglan Zheng, Shengfeng Wang, Dezheng Huo, Toshio F. Yoshimatsu, Jing Zhang, Gabriela E.S. Felix, and Olufunmilayo I. Olopade, The University of Chicago, Chicago, IL; Tom Walsh, Suleyman Gulsuner, Silvia Casadei, Ming K. Lee, and Mary-Claire King, University of Washington, Seattle, WA; Temidayo O. Ogundiran, Adeyinka Ademola, Adeyinka G. Falusi, Abideen O. Oluwasola, Adewumi Adeoye, Abayomi Odetunde, Chinedum P. Babalola, Oladosu A. Ojengbede, Stella Odedina, Imaria Anetor, University of Ibadan; Clement
– sequence: 2
  givenname: Tom
  surname: Walsh
  fullname: Walsh, Tom
  organization: Yonglan Zheng, Shengfeng Wang, Dezheng Huo, Toshio F. Yoshimatsu, Jing Zhang, Gabriela E.S. Felix, and Olufunmilayo I. Olopade, The University of Chicago, Chicago, IL; Tom Walsh, Suleyman Gulsuner, Silvia Casadei, Ming K. Lee, and Mary-Claire King, University of Washington, Seattle, WA; Temidayo O. Ogundiran, Adeyinka Ademola, Adeyinka G. Falusi, Abideen O. Oluwasola, Adewumi Adeoye, Abayomi Odetunde, Chinedum P. Babalola, Oladosu A. Ojengbede, Stella Odedina, Imaria Anetor, University of Ibadan; Clement
– sequence: 3
  givenname: Suleyman
  surname: Gulsuner
  fullname: Gulsuner, Suleyman
  organization: Yonglan Zheng, Shengfeng Wang, Dezheng Huo, Toshio F. Yoshimatsu, Jing Zhang, Gabriela E.S. Felix, and Olufunmilayo I. Olopade, The University of Chicago, Chicago, IL; Tom Walsh, Suleyman Gulsuner, Silvia Casadei, Ming K. Lee, and Mary-Claire King, University of Washington, Seattle, WA; Temidayo O. Ogundiran, Adeyinka Ademola, Adeyinka G. Falusi, Abideen O. Oluwasola, Adewumi Adeoye, Abayomi Odetunde, Chinedum P. Babalola, Oladosu A. Ojengbede, Stella Odedina, Imaria Anetor, University of Ibadan; Clement
– sequence: 4
  givenname: Silvia
  surname: Casadei
  fullname: Casadei, Silvia
  organization: Yonglan Zheng, Shengfeng Wang, Dezheng Huo, Toshio F. Yoshimatsu, Jing Zhang, Gabriela E.S. Felix, and Olufunmilayo I. Olopade, The University of Chicago, Chicago, IL; Tom Walsh, Suleyman Gulsuner, Silvia Casadei, Ming K. Lee, and Mary-Claire King, University of Washington, Seattle, WA; Temidayo O. Ogundiran, Adeyinka Ademola, Adeyinka G. Falusi, Abideen O. Oluwasola, Adewumi Adeoye, Abayomi Odetunde, Chinedum P. Babalola, Oladosu A. Ojengbede, Stella Odedina, Imaria Anetor, University of Ibadan; Clement
– sequence: 5
  givenname: Ming K.
  surname: Lee
  fullname: Lee, Ming K.
  organization: Yonglan Zheng, Shengfeng Wang, Dezheng Huo, Toshio F. Yoshimatsu, Jing Zhang, Gabriela E.S. Felix, and Olufunmilayo I. Olopade, The University of Chicago, Chicago, IL; Tom Walsh, Suleyman Gulsuner, Silvia Casadei, Ming K. Lee, and Mary-Claire King, University of Washington, Seattle, WA; Temidayo O. Ogundiran, Adeyinka Ademola, Adeyinka G. Falusi, Abideen O. Oluwasola, Adewumi Adeoye, Abayomi Odetunde, Chinedum P. Babalola, Oladosu A. Ojengbede, Stella Odedina, Imaria Anetor, University of Ibadan; Clement
– sequence: 6
  givenname: Temidayo O.
  surname: Ogundiran
  fullname: Ogundiran, Temidayo O.
  organization: Yonglan Zheng, Shengfeng Wang, Dezheng Huo, Toshio F. Yoshimatsu, Jing Zhang, Gabriela E.S. Felix, and Olufunmilayo I. Olopade, The University of Chicago, Chicago, IL; Tom Walsh, Suleyman Gulsuner, Silvia Casadei, Ming K. Lee, and Mary-Claire King, University of Washington, Seattle, WA; Temidayo O. Ogundiran, Adeyinka Ademola, Adeyinka G. Falusi, Abideen O. Oluwasola, Adewumi Adeoye, Abayomi Odetunde, Chinedum P. Babalola, Oladosu A. Ojengbede, Stella Odedina, Imaria Anetor, University of Ibadan; Clement
– sequence: 7
  givenname: Adeyinka
  surname: Ademola
  fullname: Ademola, Adeyinka
  organization: Yonglan Zheng, Shengfeng Wang, Dezheng Huo, Toshio F. Yoshimatsu, Jing Zhang, Gabriela E.S. Felix, and Olufunmilayo I. Olopade, The University of Chicago, Chicago, IL; Tom Walsh, Suleyman Gulsuner, Silvia Casadei, Ming K. Lee, and Mary-Claire King, University of Washington, Seattle, WA; Temidayo O. Ogundiran, Adeyinka Ademola, Adeyinka G. Falusi, Abideen O. Oluwasola, Adewumi Adeoye, Abayomi Odetunde, Chinedum P. Babalola, Oladosu A. Ojengbede, Stella Odedina, Imaria Anetor, University of Ibadan; Clement
– sequence: 8
  givenname: Adeyinka G.
  surname: Falusi
  fullname: Falusi, Adeyinka G.
  organization: Yonglan Zheng, Shengfeng Wang, Dezheng Huo, Toshio F. Yoshimatsu, Jing Zhang, Gabriela E.S. Felix, and Olufunmilayo I. Olopade, The University of Chicago, Chicago, IL; Tom Walsh, Suleyman Gulsuner, Silvia Casadei, Ming K. Lee, and Mary-Claire King, University of Washington, Seattle, WA; Temidayo O. Ogundiran, Adeyinka Ademola, Adeyinka G. Falusi, Abideen O. Oluwasola, Adewumi Adeoye, Abayomi Odetunde, Chinedum P. Babalola, Oladosu A. Ojengbede, Stella Odedina, Imaria Anetor, University of Ibadan; Clement
– sequence: 9
  givenname: Clement A.
  surname: Adebamowo
  fullname: Adebamowo, Clement A.
  organization: Yonglan Zheng, Shengfeng Wang, Dezheng Huo, Toshio F. Yoshimatsu, Jing Zhang, Gabriela E.S. Felix, and Olufunmilayo I. Olopade, The University of Chicago, Chicago, IL; Tom Walsh, Suleyman Gulsuner, Silvia Casadei, Ming K. Lee, and Mary-Claire King, University of Washington, Seattle, WA; Temidayo O. Ogundiran, Adeyinka Ademola, Adeyinka G. Falusi, Abideen O. Oluwasola, Adewumi Adeoye, Abayomi Odetunde, Chinedum P. Babalola, Oladosu A. Ojengbede, Stella Odedina, Imaria Anetor, University of Ibadan; Clement
– sequence: 10
  givenname: Abideen O.
  surname: Oluwasola
  fullname: Oluwasola, Abideen O.
  organization: Yonglan Zheng, Shengfeng Wang, Dezheng Huo, Toshio F. Yoshimatsu, Jing Zhang, Gabriela E.S. Felix, and Olufunmilayo I. Olopade, The University of Chicago, Chicago, IL; Tom Walsh, Suleyman Gulsuner, Silvia Casadei, Ming K. Lee, and Mary-Claire King, University of Washington, Seattle, WA; Temidayo O. Ogundiran, Adeyinka Ademola, Adeyinka G. Falusi, Abideen O. Oluwasola, Adewumi Adeoye, Abayomi Odetunde, Chinedum P. Babalola, Oladosu A. Ojengbede, Stella Odedina, Imaria Anetor, University of Ibadan; Clement
– sequence: 11
  givenname: Adewumi
  surname: Adeoye
  fullname: Adeoye, Adewumi
  organization: Yonglan Zheng, Shengfeng Wang, Dezheng Huo, Toshio F. Yoshimatsu, Jing Zhang, Gabriela E.S. Felix, and Olufunmilayo I. Olopade, The University of Chicago, Chicago, IL; Tom Walsh, Suleyman Gulsuner, Silvia Casadei, Ming K. Lee, and Mary-Claire King, University of Washington, Seattle, WA; Temidayo O. Ogundiran, Adeyinka Ademola, Adeyinka G. Falusi, Abideen O. Oluwasola, Adewumi Adeoye, Abayomi Odetunde, Chinedum P. Babalola, Oladosu A. Ojengbede, Stella Odedina, Imaria Anetor, University of Ibadan; Clement
– sequence: 12
  givenname: Abayomi
  surname: Odetunde
  fullname: Odetunde, Abayomi
  organization: Yonglan Zheng, Shengfeng Wang, Dezheng Huo, Toshio F. Yoshimatsu, Jing Zhang, Gabriela E.S. Felix, and Olufunmilayo I. Olopade, The University of Chicago, Chicago, IL; Tom Walsh, Suleyman Gulsuner, Silvia Casadei, Ming K. Lee, and Mary-Claire King, University of Washington, Seattle, WA; Temidayo O. Ogundiran, Adeyinka Ademola, Adeyinka G. Falusi, Abideen O. Oluwasola, Adewumi Adeoye, Abayomi Odetunde, Chinedum P. Babalola, Oladosu A. Ojengbede, Stella Odedina, Imaria Anetor, University of Ibadan; Clement
– sequence: 13
  givenname: Chinedum P.
  surname: Babalola
  fullname: Babalola, Chinedum P.
  organization: Yonglan Zheng, Shengfeng Wang, Dezheng Huo, Toshio F. Yoshimatsu, Jing Zhang, Gabriela E.S. Felix, and Olufunmilayo I. Olopade, The University of Chicago, Chicago, IL; Tom Walsh, Suleyman Gulsuner, Silvia Casadei, Ming K. Lee, and Mary-Claire King, University of Washington, Seattle, WA; Temidayo O. Ogundiran, Adeyinka Ademola, Adeyinka G. Falusi, Abideen O. Oluwasola, Adewumi Adeoye, Abayomi Odetunde, Chinedum P. Babalola, Oladosu A. Ojengbede, Stella Odedina, Imaria Anetor, University of Ibadan; Clement
– sequence: 14
  givenname: Oladosu A.
  surname: Ojengbede
  fullname: Ojengbede, Oladosu A.
  organization: Yonglan Zheng, Shengfeng Wang, Dezheng Huo, Toshio F. Yoshimatsu, Jing Zhang, Gabriela E.S. Felix, and Olufunmilayo I. Olopade, The University of Chicago, Chicago, IL; Tom Walsh, Suleyman Gulsuner, Silvia Casadei, Ming K. Lee, and Mary-Claire King, University of Washington, Seattle, WA; Temidayo O. Ogundiran, Adeyinka Ademola, Adeyinka G. Falusi, Abideen O. Oluwasola, Adewumi Adeoye, Abayomi Odetunde, Chinedum P. Babalola, Oladosu A. Ojengbede, Stella Odedina, Imaria Anetor, University of Ibadan; Clement
– sequence: 15
  givenname: Stella
  surname: Odedina
  fullname: Odedina, Stella
  organization: Yonglan Zheng, Shengfeng Wang, Dezheng Huo, Toshio F. Yoshimatsu, Jing Zhang, Gabriela E.S. Felix, and Olufunmilayo I. Olopade, The University of Chicago, Chicago, IL; Tom Walsh, Suleyman Gulsuner, Silvia Casadei, Ming K. Lee, and Mary-Claire King, University of Washington, Seattle, WA; Temidayo O. Ogundiran, Adeyinka Ademola, Adeyinka G. Falusi, Abideen O. Oluwasola, Adewumi Adeoye, Abayomi Odetunde, Chinedum P. Babalola, Oladosu A. Ojengbede, Stella Odedina, Imaria Anetor, University of Ibadan; Clement
– sequence: 16
  givenname: Imaria
  surname: Anetor
  fullname: Anetor, Imaria
  organization: Yonglan Zheng, Shengfeng Wang, Dezheng Huo, Toshio F. Yoshimatsu, Jing Zhang, Gabriela E.S. Felix, and Olufunmilayo I. Olopade, The University of Chicago, Chicago, IL; Tom Walsh, Suleyman Gulsuner, Silvia Casadei, Ming K. Lee, and Mary-Claire King, University of Washington, Seattle, WA; Temidayo O. Ogundiran, Adeyinka Ademola, Adeyinka G. Falusi, Abideen O. Oluwasola, Adewumi Adeoye, Abayomi Odetunde, Chinedum P. Babalola, Oladosu A. Ojengbede, Stella Odedina, Imaria Anetor, University of Ibadan; Clement
– sequence: 17
  givenname: Shengfeng
  surname: Wang
  fullname: Wang, Shengfeng
  organization: Yonglan Zheng, Shengfeng Wang, Dezheng Huo, Toshio F. Yoshimatsu, Jing Zhang, Gabriela E.S. Felix, and Olufunmilayo I. Olopade, The University of Chicago, Chicago, IL; Tom Walsh, Suleyman Gulsuner, Silvia Casadei, Ming K. Lee, and Mary-Claire King, University of Washington, Seattle, WA; Temidayo O. Ogundiran, Adeyinka Ademola, Adeyinka G. Falusi, Abideen O. Oluwasola, Adewumi Adeoye, Abayomi Odetunde, Chinedum P. Babalola, Oladosu A. Ojengbede, Stella Odedina, Imaria Anetor, University of Ibadan; Clement
– sequence: 18
  givenname: Dezheng
  surname: Huo
  fullname: Huo, Dezheng
  organization: Yonglan Zheng, Shengfeng Wang, Dezheng Huo, Toshio F. Yoshimatsu, Jing Zhang, Gabriela E.S. Felix, and Olufunmilayo I. Olopade, The University of Chicago, Chicago, IL; Tom Walsh, Suleyman Gulsuner, Silvia Casadei, Ming K. Lee, and Mary-Claire King, University of Washington, Seattle, WA; Temidayo O. Ogundiran, Adeyinka Ademola, Adeyinka G. Falusi, Abideen O. Oluwasola, Adewumi Adeoye, Abayomi Odetunde, Chinedum P. Babalola, Oladosu A. Ojengbede, Stella Odedina, Imaria Anetor, University of Ibadan; Clement
– sequence: 19
  givenname: Toshio F.
  surname: Yoshimatsu
  fullname: Yoshimatsu, Toshio F.
  organization: Yonglan Zheng, Shengfeng Wang, Dezheng Huo, Toshio F. Yoshimatsu, Jing Zhang, Gabriela E.S. Felix, and Olufunmilayo I. Olopade, The University of Chicago, Chicago, IL; Tom Walsh, Suleyman Gulsuner, Silvia Casadei, Ming K. Lee, and Mary-Claire King, University of Washington, Seattle, WA; Temidayo O. Ogundiran, Adeyinka Ademola, Adeyinka G. Falusi, Abideen O. Oluwasola, Adewumi Adeoye, Abayomi Odetunde, Chinedum P. Babalola, Oladosu A. Ojengbede, Stella Odedina, Imaria Anetor, University of Ibadan; Clement
– sequence: 20
  givenname: Jing
  surname: Zhang
  fullname: Zhang, Jing
  organization: Yonglan Zheng, Shengfeng Wang, Dezheng Huo, Toshio F. Yoshimatsu, Jing Zhang, Gabriela E.S. Felix, and Olufunmilayo I. Olopade, The University of Chicago, Chicago, IL; Tom Walsh, Suleyman Gulsuner, Silvia Casadei, Ming K. Lee, and Mary-Claire King, University of Washington, Seattle, WA; Temidayo O. Ogundiran, Adeyinka Ademola, Adeyinka G. Falusi, Abideen O. Oluwasola, Adewumi Adeoye, Abayomi Odetunde, Chinedum P. Babalola, Oladosu A. Ojengbede, Stella Odedina, Imaria Anetor, University of Ibadan; Clement
– sequence: 21
  givenname: Gabriela E.S.
  surname: Felix
  fullname: Felix, Gabriela E.S.
  organization: Yonglan Zheng, Shengfeng Wang, Dezheng Huo, Toshio F. Yoshimatsu, Jing Zhang, Gabriela E.S. Felix, and Olufunmilayo I. Olopade, The University of Chicago, Chicago, IL; Tom Walsh, Suleyman Gulsuner, Silvia Casadei, Ming K. Lee, and Mary-Claire King, University of Washington, Seattle, WA; Temidayo O. Ogundiran, Adeyinka Ademola, Adeyinka G. Falusi, Abideen O. Oluwasola, Adewumi Adeoye, Abayomi Odetunde, Chinedum P. Babalola, Oladosu A. Ojengbede, Stella Odedina, Imaria Anetor, University of Ibadan; Clement
– sequence: 22
  givenname: Mary-Claire
  surname: King
  fullname: King, Mary-Claire
  organization: Yonglan Zheng, Shengfeng Wang, Dezheng Huo, Toshio F. Yoshimatsu, Jing Zhang, Gabriela E.S. Felix, and Olufunmilayo I. Olopade, The University of Chicago, Chicago, IL; Tom Walsh, Suleyman Gulsuner, Silvia Casadei, Ming K. Lee, and Mary-Claire King, University of Washington, Seattle, WA; Temidayo O. Ogundiran, Adeyinka Ademola, Adeyinka G. Falusi, Abideen O. Oluwasola, Adewumi Adeoye, Abayomi Odetunde, Chinedum P. Babalola, Oladosu A. Ojengbede, Stella Odedina, Imaria Anetor, University of Ibadan; Clement
– sequence: 23
  givenname: Olufunmilayo I.
  surname: Olopade
  fullname: Olopade, Olufunmilayo I.
  organization: Yonglan Zheng, Shengfeng Wang, Dezheng Huo, Toshio F. Yoshimatsu, Jing Zhang, Gabriela E.S. Felix, and Olufunmilayo I. Olopade, The University of Chicago, Chicago, IL; Tom Walsh, Suleyman Gulsuner, Silvia Casadei, Ming K. Lee, and Mary-Claire King, University of Washington, Seattle, WA; Temidayo O. Ogundiran, Adeyinka Ademola, Adeyinka G. Falusi, Abideen O. Oluwasola, Adewumi Adeoye, Abayomi Odetunde, Chinedum P. Babalola, Oladosu A. Ojengbede, Stella Odedina, Imaria Anetor, University of Ibadan; Clement
BackLink https://www.ncbi.nlm.nih.gov/pubmed/30130155$$D View this record in MEDLINE/PubMed
BookMark eNp1UUtLw0AQXqRiH3r3JDnqIXEfSXZzETT4pNiLordls5m0K-mm7qaC_96E1qKCMDCH-R4z843RwDYWEDomOCIU4_OHfBZRTETERcQyzvfQiCSUh5wnyQCNMGc0JIK9DtHY-zeMSSxYcoCGDJOukmSEzu7tApxpoQyuHCjfBrmyGlxgbPBo5t1I2eClWYI9RPuVqj0cbfsEPd9cP-V34XR2e59fTkMdp7QNlUp4TGglVBbHlDBRQFqoArTCFeVZWeisZKkCztOY6YJCxrAQBVcVKVgpOJugi43ual0sodRgW6dquXJmqdynbJSRvyfWLOS8-ZApSbtbWSdwuhVwzfsafCuXxmuoa2WhWXtJcUYEpSlOOujJT6-dyfd_OgDeALRrvHdQ7SAEyz4C2UUg-wgkF7KPoKOkfyjatKo1Tb-tqf8nfgFuo4nz
CitedBy_id crossref_primary_10_1001_jamanetworkopen_2019_15989
crossref_primary_10_1200_JCO_19_00160
crossref_primary_10_1200_GO_20_00587
crossref_primary_10_1093_biomtc_ujae038
crossref_primary_10_1200_GO_20_00541
crossref_primary_10_1038_s41523_020_00214_4
crossref_primary_10_1200_EDBK_319929
crossref_primary_10_1080_14737140_2019_1582335
crossref_primary_10_1002_gcc_23275
crossref_primary_10_1093_jnci_djaa040
crossref_primary_10_1001_jamanetworkopen_2024_38091
crossref_primary_10_1002_jgc4_1374
crossref_primary_10_1007_s12609_020_00364_1
crossref_primary_10_1001_jamanetworkopen_2021_0307
crossref_primary_10_2147_BCTT_S266314
crossref_primary_10_1200_GO_21_00082
crossref_primary_10_3389_fgene_2021_759662
crossref_primary_10_3390_ijms23020628
crossref_primary_10_4103_1596_3519_356811
crossref_primary_10_1038_s41525_024_00446_4
crossref_primary_10_4103_jomt_jomt_33_20
crossref_primary_10_1038_s41576_020_00306_8
crossref_primary_10_1186_s12916_022_02260_0
crossref_primary_10_1002_mgg3_2237
crossref_primary_10_1016_j_gim_2022_03_015
crossref_primary_10_1001_jamanetworkopen_2019_10142
crossref_primary_10_1016_j_jmbbm_2022_105461
crossref_primary_10_4103_atp_atp_36_19
crossref_primary_10_1158_1055_9965_EPI_20_0564
crossref_primary_10_3389_fgene_2023_1302645
crossref_primary_10_1016_j_gde_2020_11_006
crossref_primary_10_1001_jamaoncol_2021_1492
crossref_primary_10_1002_cncr_32049
crossref_primary_10_1002_ijc_33014
crossref_primary_10_1002_gepi_22561
crossref_primary_10_3389_fgene_2021_637887
crossref_primary_10_3389_fonc_2021_732443
crossref_primary_10_1007_s10549_024_07585_3
crossref_primary_10_1158_1055_9965_EPI_22_0869
crossref_primary_10_3389_fgene_2022_834265
crossref_primary_10_1089_gtmb_2022_0160
crossref_primary_10_2147_CMAR_S382903
crossref_primary_10_2217_pgs_2019_0046
crossref_primary_10_1007_s10549_022_06557_9
crossref_primary_10_1158_1078_0432_CCR_23_1526
crossref_primary_10_1615_CritRevOncog_2024051599
crossref_primary_10_1200_EDBK_390522
crossref_primary_10_1002_cam4_2047
crossref_primary_10_1200_JCO_2018_79_3307
crossref_primary_10_1016_j_ejso_2025_109627
crossref_primary_10_1016_j_jtemin_2022_100023
crossref_primary_10_1038_s41467_021_27079_w
crossref_primary_10_3390_genes11070798
crossref_primary_10_1016_j_clbc_2020_08_010
crossref_primary_10_3390_healthcare12040462
crossref_primary_10_1093_jnci_djac090
crossref_primary_10_1038_s41598_022_04791_1
crossref_primary_10_1007_s10549_022_06560_0
crossref_primary_10_1002_ijc_34671
crossref_primary_10_1200_GO_21_00140
crossref_primary_10_1200_GO_23_00154
crossref_primary_10_1093_hmg_ddab180
crossref_primary_10_1007_s12253_019_00586_4
crossref_primary_10_1053_j_seminoncol_2023_12_001
crossref_primary_10_11648_j_wjph_20240902_18
crossref_primary_10_1158_1055_9965_EPI_19_0506
crossref_primary_10_1200_OP_21_00236
crossref_primary_10_3389_fonc_2023_1240098
crossref_primary_10_1158_1055_9965_EPI_21_1397
crossref_primary_10_1007_s12553_021_00637_4
crossref_primary_10_1016_j_canep_2020_101739
crossref_primary_10_1126_science_aay4743
crossref_primary_10_1002_sim_10323
crossref_primary_10_2174_1568009620666201009125507
crossref_primary_10_1200_GO_21_00089
crossref_primary_10_1038_s41571_020_0428_5
crossref_primary_10_1016_j_canep_2022_102195
crossref_primary_10_1093_jnci_djae334
crossref_primary_10_1002_humu_23804
crossref_primary_10_1186_s13058_023_01627_2
crossref_primary_10_3389_fonc_2020_606400
Cites_doi 10.1056/NEJMsr1501341
10.1093/aje/kwq180
10.1002/cncr.29010
10.1002/bjs.1800790819
10.1007/s10549-010-1006-9
10.1136/jmg.2004.020446
10.1007/s13167-010-0037-y
10.1073/pnas.1007983107
10.1046/j.1365-2168.1999.01117.x
10.1016/j.annepidem.2013.06.008
10.1001/jamaoncol.2015.5495
10.3322/caac.21271
10.1126/science.7545954
10.1038/sj.bjc.6604275
10.1007/s10549-014-3195-0
10.1073/pnas.1115052108
10.1158/1055-9965.EPI-14-0675
10.1073/pnas.1415979111
10.1186/s13058-014-0474-y
10.1200/JCO.2014.57.1414
10.1126/science.1088759
10.1002/cncr.24200
10.1200/JCO.2008.19.6873
10.1007/s12687-017-0311-y
10.1186/1471-2164-12-184
10.1007/s10549-012-2136-z
10.1002/ijc.27326
10.1158/0008-5472.CAN-06-0503
10.1016/j.canep.2012.04.007
10.1158/1055-9965.EPI-11-0775
ContentType Journal Article
Copyright 2018 by American Society of Clinical Oncology 2018 American Society of Clinical Oncology
Copyright_xml – notice: 2018 by American Society of Clinical Oncology 2018 American Society of Clinical Oncology
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
5PM
DOI 10.1200/JCO.2018.78.3977
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic
MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Pharmacy, Therapeutics, & Pharmacology
DocumentTitleAlternate Inherited Breast Cancer in Nigerian Women
EISSN 1527-7755
EndPage 2825
ExternalDocumentID PMC6161833
30130155
10_1200_JCO_2018_78_3977
Genre Research Support, Non-U.S. Gov't
Journal Article
Research Support, N.I.H., Extramural
GeographicLocations Nigeria
GeographicLocations_xml – name: Nigeria
GrantInformation_xml – fundername: NCI NIH HHS
  grantid: K12 CA139160
– fundername: NCI NIH HHS
  grantid: U01 CA161032
GroupedDBID ---
.55
0R~
18M
2WC
34G
39C
4.4
53G
5GY
5RE
8F7
AAQQT
AARDX
AAWTL
AAYEP
AAYOK
AAYXX
ABBLC
ABJNI
ABOCM
ACGFO
ACGFS
ACGUR
ADBBV
AEGXH
AENEX
AIAGR
ALMA_UNASSIGNED_HOLDINGS
BAWUL
BYPQX
C45
CITATION
CS3
DIK
EBS
EJD
F5P
F9R
FBNNL
FD8
GX1
H13
HZ~
IH2
K-O
KQ8
L7B
LSO
MJL
N9A
O9-
OK1
OVD
OWW
P2P
QTD
R1G
RHI
RLZ
RUC
SJN
TEORI
TR2
TWZ
UDS
VVN
WH7
X7M
YFH
YQY
CGR
CUY
CVF
ECM
EIF
NPM
7X8
5PM
ID FETCH-LOGICAL-c462t-aa57412f8a9442138be6babeca0f279dbc9d36ae77643cb2e93088b7af1b3d873
ISSN 0732-183X
1527-7755
IngestDate Thu Aug 21 14:35:23 EDT 2025
Mon Jul 21 09:33:12 EDT 2025
Mon Jul 21 06:04:28 EDT 2025
Tue Jul 01 02:13:14 EDT 2025
Thu Apr 24 23:07:47 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 28
Language English
License Licensed under the Creative Commons Attribution 4.0 License: http://creativecommons.org/licenses/by/4.0
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c462t-aa57412f8a9442138be6babeca0f279dbc9d36ae77643cb2e93088b7af1b3d873
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
M.-C.K. and O.I.O. contributed equally to this work.
Deceased.
Y.Z. and T.W. contributed equally to this work.
OpenAccessLink https://pubmed.ncbi.nlm.nih.gov/PMC6161833
PMID 30130155
PQID 2091822605
PQPubID 23479
PageCount 6
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_6161833
proquest_miscellaneous_2091822605
pubmed_primary_30130155
crossref_primary_10_1200_JCO_2018_78_3977
crossref_citationtrail_10_1200_JCO_2018_78_3977
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2018-10-01
PublicationDateYYYYMMDD 2018-10-01
PublicationDate_xml – month: 10
  year: 2018
  text: 2018-10-01
  day: 01
PublicationDecade 2010
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle Journal of clinical oncology
PublicationTitleAlternate J Clin Oncol
PublicationYear 2018
Publisher American Society of Clinical Oncology
Publisher_xml – name: American Society of Clinical Oncology
References B20
B21
B22
B23
B25
B26
B27
B28
B29
B30
B31
B10
B11
B12
B13
B14
B15
B16
B17
B18
B19
B1
B2
B3
B4
B5
B6
B7
B8
B9
30130156 - J Clin Oncol. 2018 Oct 1;36(28):2817-2819. doi: 10.1200/JCO.2018.79.3307
References_xml – ident: B10
  doi: 10.1056/NEJMsr1501341
– ident: B12
  doi: 10.1093/aje/kwq180
– ident: B21
  doi: 10.1002/cncr.29010
– ident: B2
  doi: 10.1002/bjs.1800790819
– ident: B6
  doi: 10.1007/s10549-010-1006-9
– ident: B5
  doi: 10.1136/jmg.2004.020446
– ident: B28
  doi: 10.1007/s13167-010-0037-y
– ident: B9
  doi: 10.1073/pnas.1007983107
– ident: B1
  doi: 10.1046/j.1365-2168.1999.01117.x
– ident: B13
  doi: 10.1016/j.annepidem.2013.06.008
– ident: B29
  doi: 10.1001/jamaoncol.2015.5495
– ident: B30
  doi: 10.3322/caac.21271
– ident: B18
  doi: 10.1126/science.7545954
– ident: B11
  doi: 10.1038/sj.bjc.6604275
– ident: B27
  doi: 10.1007/s10549-014-3195-0
– ident: B15
  doi: 10.1073/pnas.1115052108
– ident: B14
  doi: 10.1158/1055-9965.EPI-14-0675
– ident: B23
  doi: 10.1073/pnas.1415979111
– ident: B26
  doi: 10.1186/s13058-014-0474-y
– ident: B17
  doi: 10.1200/JCO.2014.57.1414
– ident: B22
  doi: 10.1126/science.1088759
– ident: B20
  doi: 10.1002/cncr.24200
– ident: B3
  doi: 10.1200/JCO.2008.19.6873
– ident: B31
  doi: 10.1007/s12687-017-0311-y
– ident: B16
  doi: 10.1186/1471-2164-12-184
– ident: B8
  doi: 10.1007/s10549-012-2136-z
– ident: B7
  doi: 10.1002/ijc.27326
– ident: B19
  doi: 10.1158/0008-5472.CAN-06-0503
– ident: B4
  doi: 10.1016/j.canep.2012.04.007
– ident: B25
  doi: 10.1158/1055-9965.EPI-11-0775
– reference: 30130156 - J Clin Oncol. 2018 Oct 1;36(28):2817-2819. doi: 10.1200/JCO.2018.79.3307
SSID ssj0014835
Score 2.5485318
Snippet Among Nigerian women, breast cancer is diagnosed at later stages, is more frequently triple-negative disease, and is far more frequently fatal than in Europe...
SourceID pubmedcentral
proquest
pubmed
crossref
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage 2820
SubjectTerms Adult
Breast Neoplasms - epidemiology
Breast Neoplasms - genetics
Female
Genetic Predisposition to Disease
Humans
Middle Aged
Mutation
Nigeria - epidemiology
ORIGINAL REPORTS
Title Inherited Breast Cancer in Nigerian Women
URI https://www.ncbi.nlm.nih.gov/pubmed/30130155
https://www.proquest.com/docview/2091822605
https://pubmed.ncbi.nlm.nih.gov/PMC6161833
Volume 36
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3tT9QwGG8UE8IXI_h2IqYmhoTADtbu1u0jLhrQICQeCfpl6bpOLjl2hG0m-NfzPG23u4EY9Utzt_W6XX9Pn_7aPi-EvIvjYk_CTO2NFB95wG-VJ4HWQhEXOXyTXOM-5NGX8OA0-HQ2OmtzuDvvkjobql-_9Sv5H1ThGuCKXrL_gGzXKFyAz4AvlIAwlH-F8WGJ3nvIGd-jbXm9nSCGaGAOCP_ANyi3TYrKeyho5xY5K1Vve_37ubY64NvMJPlY2HavzD7M2P4bY7nTTKumzd_VgI65mNdPZCVzbQwGvk6mPydycZPBjzpzNZgjnGJkApi4Danbak4busRJiPPxdnowMi5udxU0s7mnk2O0qouGIhoiA12sCl18eWEA43iq6rtH9oNit7cekkdMAGlCNnz4uTs-CoBXujNpeODu7cetkOW2gT4dubPGuG0qu8A9xk_IY4cY3bcSsEoe6HKNLB85s4g1snliA5Bf79Dx3J-u2qGb9GQemvz6KdnqJIZaiaFWYuikpK3EUCMxz8jpxw_j5MBzyTI8FYSs9iQMscBnRSTjIGA-jzIdZhJGqNwrmIjzTMU5D6UWAjioypiOOUwwmZCFn_E8Evw5WSpnpX5JqFSFHyhYa8L1QEQSFmGaQbV8FIoCuMyA7LZ9lioXSR4TmkxTXFEyPB5NjlPs8FREKXb4gGx1v7i0UVT-UPdtC0MKqg7Pr2SpZ00FtWJYDeMCfEBeWFi61lo8B0T0AOsqYBj1_p1ycm7CqYeYM4LzV_e2uU5W5mPiNVmqrxq9AVS0zt4YsbsBO66Fyw
linkProvider Flying Publisher
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Inherited+Breast+Cancer+in+Nigerian+Women&rft.jtitle=Journal+of+clinical+oncology&rft.au=Zheng%2C+Yonglan&rft.au=Walsh%2C+Tom&rft.au=Gulsuner%2C+Suleyman&rft.au=Casadei%2C+Silvia&rft.date=2018-10-01&rft.eissn=1527-7755&rft.volume=36&rft.issue=28&rft.spage=2820&rft_id=info:doi/10.1200%2FJCO.2018.78.3977&rft_id=info%3Apmid%2F30130155&rft.externalDocID=30130155
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0732-183X&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0732-183X&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0732-183X&client=summon